In vivo models for cancer stem cell research: A practical guide for frequently used animal models and available biomarkers

Journal of Physiology and Pharmacology

Volumn 65, Issue 2, 2014, Pages 157-169

  Skidan, I ^a   Steiniger, Sebastian C J ^b  

^a Pharmapt Inc   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Biomarkers; Cancer stem cells; Humanized mice; Immunodeficient mice; Patient derived xenograft; Tumor models

Indexed keywords

ABC TRANSPORTER B5; ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; CD133 ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CELL MARKER; DEMCIZUMAB; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MICRORNA 21; MICRORNA 34A; MK 0752; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; NESTIN; PEPTIDE; PYRIDOXINE; REPARIXIN; SALINOMYCIN; SARIDEGIB; SOMATOMEDIN C RECEPTOR MONOCLONAL ANTIBODY; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANTICTUMAB; VASCULAR ENDOTHELIAL CADHERIN; VISMODEGIB; ANTINEOPLASTIC AGENT;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; BIOLOGICAL MODEL; BREAST CANCER; CANCER STEM CELL; CANCER TRANSPLANTATION; CARCINOGENICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DISRUPTION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; IMMUNE SYSTEM; MEDULLOBLASTOMA; MESENCHYMAL STEM CELL; METASTASIS; NOD SCID MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TARGET CELL; TOXICITY TESTING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; STEM CELL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HUMANS; MODELS, ANIMAL; NEOPLASTIC STEM CELLS; STEM CELL RESEARCH;

EID: 84899650498     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
2. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296.
3. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
4. Diaz A, Leon K. Therapeutic approaches to target cancer stem cells. Cancers (Basel) 2011; 3: 3331-3352.
5. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
6. Naujokat C. Targeting Human Cancer Stem Cells with Monoclonal Antibodies. J Clin Cell Immunol 2012; S5: 007.
7. Perlstein B, Finniss SA, Miller C, et al. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol 2013; 15: 29-40.
8. Zhou L, Yang ZX, Song WJ, et al. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol 2013; 43: 661-669.
9. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215.
10. Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011; 6: e27306.
11. Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009; 69: 7672-7680.
12. Hart S, Novotny-Diermayr V, Goh KC, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther 2013; 12: 151-161.
13. Lee H, Kim JB, Park SY, Kim SS, Kim H. Combination effect of paclitaxel and hyaluronic acid on cancer stemlike side population cells. J Biomed Nanotechnol 2013; 9: 299-302.
14. Fang DD, Cao J, Jani JP, et al. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Front Med 2013; 7: 462-476.
15. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
16. Li RJ, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release 2011; 149: 281-291.
17. Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J Pharm Pharm Sci 2010; 13: 136-151.
18. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011; 11: 464-473.
19. Burke AR, Singh RN, Carroll DL, et al. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012; 33: 2961-2970.
20. Herrmann I, Baeuerle PA, Friedrich M, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One 2010; 5: e13474.
21. Perez, A, Neskey DM, Wen J, et al. Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083. Cancer Res 2012; 72 (Suppl. 1): abstract 2521. doi: 10.1158/1538-7445.AM2012-2521
22. Korbut E, Ptak-Belowska A, Brzozowski T. Mechanisms promoting physiological cells progression into tumorigenesis. J Physiol Pharmacol 2012; 63: 565-570.
23. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12: 14.
24. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012; 19: 60-71.
25. Jackson AL. Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010; 9: 57-67.
26. Seth S, Johns R, Templin MV. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv 2012; 3: 245-261.
27. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptidespecific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58: 4902-4908.
28. Sahr RN. The Biologics Price Competition and Innovation Act: Innovation Must Come Before Price Competition 2 (Boston College Intellectual Prop. & Tech. Forum 2009). http://bciptf.org/?s=The+biologics+price+competition+and +innovation+act%3A+Innovation+must+come+before+pric e+competition
29. Materials at http://foundation.aarp.org.
30. Kruger FA, Overington JP. Global analysis of small molecule binding to related protein targets. PLoS Comput Biol 2012; 8: e1002333.
31. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012; 6: 155-176.
32. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
33. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63: 131-135.
34. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759-767.
35. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V. In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 2009; 16: 45-51.
36. Skidan I, Dholakia P, Torchilin V. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J Drug Target 2008; 16: 486-493.
37. Miao B, Skidan I, Yang J, et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci USA 2010; 107: 20126-20131.
38. Zamboni WC, Torchilin V, Patri AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012; 18: 3229-3241.
39. Kim TH, Mount CW, Gombotz WR, Pun SH. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 2010; 31: 7386-7397.
40. Bourseau-Guilmain E, Bejaud J, Griveau A, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm 2012; 423: 93-101.
41. Upadhyay KK, Bhatt AN, Mishra AK, et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010; 31: 2882-2892.
42. Banzato A, Bobisse S, Rondina M, et al. A paclitaxelhyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008; 14: 3598-3606.
43. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012; 7: 597-615.
44. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem 2013; 59: 85-93.
45. Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
46. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nature Rev Cancer 2009; 9: 143.
47. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013; 238: 324-338. Epub 2013/04/20.
48. Sano A, Kato H, Sakurai S, et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16: 506-514.
49. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006; 66: 4553-4557.
50. Borovski T, De Sousa EM, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011; 71: 634-639.
51. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292: C987-C995.
52. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
53. Shiozawa Y, Taichman RS. Cancer stem cells and the bone marrow microenvironment. Bonekey Rep 2012; 2012: 48.
54. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010; 9: 2450-2457.
55. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
56. Madka V, Rao CV. Cancer stem cell markers as potential targets for epithelial cancers. Indian J Exp Biol 2011; 49: 826-835.
57. Han ME, Oh SO. Gastric stem cells and gastric cancer stem cells. Anat Cell Biol 2013; 46: 8-18.
58. Riether C, Schurch C, Ochsenbein AF. From "magic bullets" to specific cancer immunotherapy. Swiss Med Wkly 2013; 143: w13734. doi: 10.4414/smw.2013.13734.
59. Hill RP, Perris R. "Destemming" cancer stem cells. J Nat Cancer Inst 2007; 99: 1435-1440.
60. Tu LC, Foltz G, Lin E, Hood L, Tian Q. Targeting stem cellsclinical implications for cancer therapy. Curr Stem Cell Res Ther 2009; 4: 147-153.
61. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950-5954.
62. Klonisch T, Wiechec E, Hombach-Klonisch S, et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14:450-460.
63. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887.
64. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
65. Ponnusamy MP, Batra SK. Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 2008; 1: 4.
66. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
67. Steiniger SC, Coppinger JA, Kruger JA, Yates J, Janda KD. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 2008; 26: 3037-3046.
68. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
69. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009; 15: 135-147.
70. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
71. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
72. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-2284.
73. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
74. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991; 9: 323-350.
75. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182.
76. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
77. Ong GL, Baker AE, Mattes MJ. Analysis of high complement levels in Mus hortulanus and BUB mice. J Immunol Methods 1992; 154: 37-45.
78. van der Loo JC, Hanenberg H, Cooper RJ, Luo FY, Lazaridis EN, Williams DA. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood 1998; 92: 2556-2570.
79. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002; 99: 4100-4108.
80. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-349.
81. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Nat Cancer Inst 1993; 85: 394-398.
82. Bosma MJ. B and T cell leakiness in the scid mouse mutant. Immunodefic Rev 1992; 3: 261-276.
83. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489.
84. Rolstad B. The athymic nude rat: an animal experimental model to reveal novel aspects of innate immune responses? Immunol Rev 2001; 184: 136-144.
85. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007; 170: 793-804.
86. Kruger JA, Kaplan CD, Luo Y, et al. Characterization of stem cell-like cancer cells in immune-competent mice. Blood 2006; 108: 3906-3912.
87. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
88. Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD. Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) coinjection. Nat Protoc 2012; 7: 1138-144.
89. Alonso-Camino V, Santos-Valle P, Ispizua MC, Sanz L, Alvarez-Vallina L. Engineered human tumor xenografts with functional human vascular networks. Microvasc Res 2011; 81: 18-25.
90. Decaudin D. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anticancer Drugs 2011; 22: 827-841.
91. Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol 2012; 2012: 568567.
92. Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 2005; 11: 1713-1721.
93. Gelbard A, Kupferman ME, Jasser SA, et al. An orthotopic murine model of sinonasal malignancy. Clin Cancer Res 2008; 14: 7348-7357.
94. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer 2008; 98: 1886-1893.
95. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res 2012; 18: 4277-4284.
96. Masood R, Hochstim C, Cervenka B, et al. A novel orthotopic mouse model of head and neck cancer and lymph node metastasis. Oncogenesis 2013; 2: e68.
97. Yae T, Tsuchihashi K, Ishimoto T, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012; 3: 883. doi: 10.1038/ncomms1892
98. Du L, Rao G, Wang H, et al. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res 2013; 73: 2682-2694.
99. La Porta CA. Thoughts about cancer stem cells in solid tumors. World J Stem Cells 2012; 4: 17-20.
100. Ruggeri BA, Camp F. Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug Discovery. Biochem Pharmacol 2013; 87: 150-161.
101. van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med 2010; 7: e1000245. doi: 10.1371/journal.pmed.1000245.
102. Francipane MG, Chandler J, Lagasse E. Cancer stem cells: a moving target. Curr Pathobiol Rep 2013; 1: 111-118.
103. Lathia JD, Gallagher J, Myers JT, et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PloS One 2011; 6: e24807. doi: 10.1371/journal.pone.0024807.
104. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
105. Curtis SJ, Sinkevicius KW, Li D, et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010; 7: 127-133.
106. Cheng L, Ramesh AV, Flesken-Nikitin A, Choi J, Nikitin AY. Mouse models for cancer stem cell research. Toxicol Pathol 2010; 38: 62-71.
107. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12: 767-775.
108. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
109. Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27: 1734-1740.
110. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
111. Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992; 255: 1137-1141.
112. Shih CC, Hu J, Arber D, LeBon T, Forman SJ. Transplantation and growth characteristics of human fetal lymph node in immunodeficient mice. Exp Hematol 2000; 28: 1046-1053.
113. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
114. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nature Rev Immunol 2012; 12: 786-798.
115. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 120-125.
116. Shankar S, Nall D, Tang SN, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PloS One 2011; 6: e16530.
117. Fu J, Rodova M, Roy SK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett 2013; 330: 22-32.
118. Wege AK, Ernst W, Eckl J, et al. Humanized tumor mice-a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer 2011; 129: 2194-2206.
119. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Nat Acad Sci USA 2004; 101: 4966-4971.
120. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Nat Acad Sci USA 2011; 108: 6468-6473.
121. Doyle A, McGarry MP, Lee NA, Lee JJ. The construction of transgenic and gene knockout/knockin mouse models of human disease. Transgenic Res 2012; 21: 327-349.
122. Wolfer DP, Crusio WE, Lipp HP. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci 2002; 25: 336-340.
123. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 2011; 29: 2273-2281.
124. Snippert HJ, van Es JH, van den Born M, et al. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 2009; 136: 2187-2194.
125. Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Nat Acad Sci USA 2012; 109: 11717-11722.
126. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957.